Monday, June 15, 2026

Under Fire: How South Korea’s Military Aid Could Change the Tide in Ukraine

The South Korean government has decided to reconsider its weapon support for Ukraine in response to the North Korea -Russia treaty.

Revolutionary Cancer Treatment SJ-650: What Makes It a Game Changer in Oncology?

SillaJen's SJ-650 cancer treatment platform gains recognition with publication in Molecular Therapy, showcasing its innovative approach and efficacy.

7 Years Later: Is the 9/19 Military Agreement on the Brink of Collapse?

The 9·19 military agreement, signed in 2018 under the watch of North and South Korean leaders, marks its 7th anniversary but has stalled.

Tag: Medipost

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

CARTISTEM vs. Traditional Treatments: What Makes Medipost’s Stem Cell Therapy a Game-Changer?

Medipost to commercialize CARTISTEM in Japan using domestically produced media, enhancing supply chain stability and competitiveness.

Medipost Reports Positive Phase 3 Results for CARTISTEM in Japan’s Knee Osteoarthritis Trial

Medipost's CARTISTEM therapy shows significant efficacy in Phase 3 trials for knee osteoarthritis in Japan, enhancing global competitiveness.

Medipost’s CARTISTEM® Completes Phase 3 Trials in Japan: What This Means for Knee Osteoarthritis Treatment

Medipost completes Phase 3 trial for CARTISTEM in Japan, targeting knee osteoarthritis treatment and planning U.S. trial enrollment soon.

Medipost’s Cartistem: Achieving 3000 Knee Cartilage Restoration Surgeries – A Game Changer for Osteoarthritis Treatment

Medipost's Cartistem therapy reaches 3,000 procedures for cartilage restoration, proving its safety and efficacy for knee osteoarthritis.

U.S. Surgeons Get Hands-On With Korea’s Game-Changing Stem Cell Therapy

Medipost's Cartistem® training program for U.S. orthopedic specialists enhances global collaboration and prepares for Phase 3 trials.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.